A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
- Registration Number
- NCT01310816
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Brief Summary
IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma.
- Detailed Description
Study IPI-926-04 is a Phase 2, double-blind, placebo-controlled, multicenter, trial evaluating the safety and efficacy of IPI-926 in patients with metastatic or locally advanced (unresectable) chondrosarcoma. The study includes an optional cross-over to open-label IPI-926 for patients randomly assigned to placebo who experience documented disease progression.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 105
- At least 18 years of age at the time of signing informed consent.
- Pathologically diagnosed conventional chondrosarcoma. Patients must have tumor sample(s) available or provide tumor samples from a new biopsy
- Metastasis to at least 1 location or locally advanced disease that is deemed unresectable by a surgeon
- At least 1 radiologically measurable target lesion per RECIST 1.1.
- Patients must have documented radiographic progression of disease within the 6-month period prior to screening. (MRI or CT Scan)
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
- Life expectancy of at least 3 months
- All women of child-bearing potential (WCBP), all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control throughout the study and for 30 days after the last dose of study drug.
- Ability to adhere to the study visit schedule and all protocol requirements.
- Voluntarily signed an informed consent form.
- Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer.
- Systemic anti-cancer therapy within 21 days prior to the first dose of study drug, or radiotherapy within 14 days prior to the first dose of study drug.
- Prior treatment with a Hedgehog pathway inhibitor
- Medically significant surgical procedures or significant traumatic injury within 28 days before Day 1.
- Inadequate hematologic function defined by:
- Hemoglobin <8.0 g/dL (80 g/L) (may be increased to this level with transfusion as long as there is no evidence of active bleeding).
- Inadequate hepatic function defined by:
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN).
- Total bilirubin >1.5 x ULN (with the exception of patients with Gilbert's disease).
- Cirrhotic liver disease, ongoing alcohol abuse, or known chronic active or acute hepatitis.
- Inadequate renal function defined by serum creatinine >1.5 x ULN
- Patients with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months.
- Presence of active infection or systemic use of antibiotics within 72 hours of treatment.
- Significant co-morbid condition or disease, which in the judgment of the Investigator, would place the patient at undue risk or interfere with the study. Examples include, but are not limited to sepsis and recent significant traumatic injury.
- Known human immunodeficiency virus (HIV) positivity.
- Known hypersensitivity to IPI-926, or any of the excipients in IPI-926 or placebo capsules.
- Pregnant or lactating women.
- Current administration of the medications or foods which are known to be moderate or strong inhibitors of CYP3A4 activity
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description IPI-926 IPI-926 IPI-926 Sugar Pill Placebo Arm Placebo Arm, sugar pill
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) estimated 6 months * To compare progression-free survival (PFS) in patients with metastatic or locally advanced (unresectable) chondrosarcoma administered IPI-926 or placebo.
* Number of Incidence of reported adverse events and abnormal laboratory test results. To evaluate the safety of IPI-926 or placebo in patients with metastatic or locally advanced (unresectable) chondrosarcoma
- Secondary Outcome Measures
Name Time Method Comparison of Time To Progression (TTP) estimated 6 months \*To compare, Time To Progression (TTP) with metastatic or locally advanced (unresectable) chondrosarcoma patients administered IPI-926 or placebo
Comparison of Overall Survival (OS) estimated 6 months To compare Overall Survival (OS) with metastatic or locally advanced (unresectable) chondrosarcoma patients administered IPI-926 or placebo
Overall Response Rate (ORR) estimated 6 months To compare Overall Response Rate (ORR) with metastatic or locally advanced (unresectable) chondrosarcoma patients administered IPI-926 or placebo
Trial Locations
- Locations (36)
Sarcoma Oncology Center
🇺🇸Santa Monica, California, United States
University of Miami - Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Institut de Cancérologie Gustave Roussy
🇫🇷Villejuif, Ile-de-france, France
Leids Unversitair Medisch Centrum
🇳🇱Leiden, Zuid-Holland, Netherlands
Centre Léon Bérard, Service d'Oncologie Médicale
🇫🇷Lyon, Rhone-alpes, France
Monash Medical Centre
🇦🇺East Bentleigh, Victoria, Australia
Radiumhospitalet
🇳🇴Oslo, Norway
Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Warszawie
🇵🇱Warszawa, Mazowieckie, Poland
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
OHSU Knight Cancer Institute
🇺🇸Portland, Oregon, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Washington University in St. Louis
🇺🇸St. Louis, Missouri, United States
Sydney Cancer Centre
🇦🇺Camperdown, New South Wales, Australia
(TGen) Translational Genomics Research Institute
🇺🇸Scottsdale, Arizona, United States
Pennsylvania Oncology Hematology Associates
🇺🇸Philadelphia, Pennsylvania, United States
Centre René Gauducheau
🇫🇷Saint Herblain cedex, Pays de La Loire, France
Universitätsklinikum Essen
🇩🇪Essen, Nordrhein-westfalen, Germany
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
University of Washington - Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Universitätsmedizin Mannheim
🇩🇪Mannheim, Baden-wuerttemberg, Germany
Medizinische Universität Wien
🇦🇹Wien, Vienna, Austria
Helios Klinikum Bad Saarow
🇩🇪Bad Saarow, Brandenburg, Germany
IRCCS Istituto Ortopedico Rizzoli
🇮🇹Bologna, Italy
Newcastle General Hospital
🇬🇧Newcastle Upon Tyne, England, United Kingdom
SI Russian Oncological Research Center
🇷🇺Moscow, Russian Federation
Royal Orthopaedic Hospital
🇬🇧Birmingham, England, United Kingdom
Moscow n.a. P.A Herzen Oncology Research Institute of Rosmedtechnologies
🇷🇺Moscow, Russian Federation
Skånes Universitetssjukhus
🇸🇪Lund, Skane, Sweden
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
University College Hospital
🇬🇧London, England, United Kingdom